DEF: Quince Therapeutics Seeks Stockholder Approval for Key Proposals

Quince Therapeutics, Inc. is holding a Special Meeting of Stockholders on October 6, 2026, to vote on several proposals, including the issuance of shares related to its recent acquisition of Orphai Therapeutics and a private placement.

Summary

• Quince Therapeutics, Inc. is convening a Special Meeting of Stockholders on October 6, 2026, to vote on six proposals.
• The meeting will be held virtually, with stockholders of record as of August 24, 2026, eligible to vote.
• Key proposals include approving the issuance of shares related to the acquisition of Orphai Therapeutics and a concurrent private placement, which will result in significant dilution and potential change of control under Nasdaq rules.
• Stockholders will also vote on increasing the authorized common stock, approving new equity incentive and employee stock purchase plans, and authorizing the adjournment of the meeting if necessary.
• The company completed the acquisition of Orphai Therapeutics on May 18, 2026, and a private placement on May 21, 2026, raising approximately $115 million.
• New executive leadership is planned, contingent on the approval of these proposals, with the CEO, CFO, and COO roles expected to change.
• The company anticipates changing its name to IRulya Therapeutics Inc. and trading under the symbol IRLA if the proposals are approved.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, primarily due to the strategic acquisition and financing, though it highlights the need for stockholder approval on several key proposals that could impact share structure and control.

Positives

• Successful acquisition of Orphai Holdings Therapeutics, Inc. and Orphai Therapeutics, LLC on May 18, 2026.
• Completion of a 2026 Private Placement on May 21, 2026, raising approximately $115 million in gross proceeds.
• Strategic focus on advancing LAM-001, Orphai's lead product candidate, through clinical milestones.
• Proposed new leadership team with Brigette Roberts, M.D., as CEO, John Militello as CFO, and Keith Fandrick as COO.
• The Board of Directors unanimously recommends voting FOR all six proposals.

Negatives

• Significant dilution to existing stockholders is expected upon conversion of Series C Preferred Stock and exercise of warrants and options.
• Potential change of control implications under Nasdaq Listing Rule 5635(b) require stockholder approval.
• Failure to obtain stockholder approval for key proposals could lead to cash settlement obligations for Series C Preferred Stock, potentially harming financial condition.
• The company is subject to Nasdaq listing rules that require stockholder approval for significant share issuances.
• The acquisition was accounted for as an asset acquisition due to Orphai not meeting the definition of a business under ASC 805, resulting in an acquisition loss.

Risks

• Failure to obtain stockholder approval for Proposals 1, 2, and 3 could result in cash settlement of Series C Preferred Stock, materially harming operations and financial condition.
• Failure to meet Nasdaq initial listing requirements or obtain approval of the Nasdaq Listing Application could materially affect operations and business.
• The issuance of additional authorized shares of common stock may have a dilutive effect on earnings per share and voting rights.
• The company may be required to adjourn or postpone the Special Meeting multiple times if sufficient votes are not obtained, incurring significant costs.
• The unaudited pro forma financial information is preliminary and may not accurately reflect the future financial condition.
• The company is subject to Section 203 of the DGCL, which may deter certain business combinations.

Future Outlook

The company expects to advance LAM-001 through key clinical milestones, including Phase 2 data in Bronchiolitis Obliterans Syndrome, Phase 2 data in pulmonary hypertension associated with interstitial lung disease, and Phase 2 data in sarcoidosis associated pulmonary hypertension, using proceeds from the private placement. The company also anticipates a name change to IRulya Therapeutics Inc. and trading under the symbol IRLA, subject to stockholder approval.

Management Comments

• The Board has unanimously determined to recommend that our stockholders vote FOR the Conversion Proposal, FOR the Minimum Price Proposal, FOR the Authorized Share Proposal, FOR the 2026 Plan Proposal, FOR the 2026 ESPP Proposal and FOR the Adjournment Proposal.
• We urge you to read the Proxy Statement carefully and in its entirety. Your vote is important.

Industry Context

StockSavvy.ai notes that the biotechnology sector continues to face challenging capital markets, prompting companies like Quince Therapeutics to pursue strategic transactions and financing to advance their pipelines. The need for stockholder approval for significant share issuances and potential changes in control is a common requirement driven by exchange listing rules.

Management Changes

Related Party Transactions

• Support Agreements were entered into with certain officers and directors (in their capacity as stockholders) representing approximately 2.9% of outstanding shares, agreeing to vote in favor of Proposals 1, 2, and 3.

Stakeholder Impact

• Existing stockholders will experience dilution in their economic and voting interests due to the issuance of new shares.
• Employees may benefit from the proposed 2026 Equity Incentive Plan and 2026 ESPP.
• Management and Board composition is expected to change, subject to stockholder approval.

Next Steps

• Stockholders to vote on Proposals 1 through 6 at the Special Meeting on October 6, 2026.
• If Proposals 1-3 are approved, Series C Preferred Stock will convert into common stock, Warrants and Orphai Options will become exercisable for common stock, and management/board changes will occur.
• If approved, the company expects to change its name to IRulya Therapeutics Inc. and trade under the symbol IRLA.
• The company will file a resale registration statement with the SEC within 75 days following the closing of the 2026 Private Placement.
• If the 2026 Plan and 2026 ESPP are approved, the company intends to file registration statements on Form S-8.

Key Dates

Recommendation

The acquisition and financing are positive steps, but the significant dilution and reliance on stockholder approval for critical Nasdaq compliance and strategic execution introduce considerable uncertainty. While the company is advancing its pipeline, the immediate impact of share dilution and the potential for further delays if approvals are not met warrant a cautious 'hold' stance until the outcomes of the shareholder vote are clear and the company demonstrates progress under the new structure.

Keywords

Special Meeting, Stockholder Approval, Acquisition, Orphai Therapeutics, Private Placement, Series C Preferred Stock, Warrants, Equity Incentive Plan, Employee Stock Purchase Plan, Nasdaq Listing Rules